vs

Side-by-side financial comparison of Arteris, Inc. (AIP) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $20.1M, roughly 1.9× Arteris, Inc.). Arteris, Inc. runs the higher net margin — -42.2% vs -161.8%, a 119.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 30.0%). Arteris, Inc. produced more free cash flow last quarter ($3.0M vs $-71.3M).

Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

AIP vs IBRX — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.9× larger
IBRX
$38.3M
$20.1M
AIP
Growing faster (revenue YoY)
IBRX
IBRX
+376.9% gap
IBRX
407.0%
30.0%
AIP
Higher net margin
AIP
AIP
119.6% more per $
AIP
-42.2%
-161.8%
IBRX
More free cash flow
AIP
AIP
$74.3M more FCF
AIP
$3.0M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AIP
AIP
IBRX
IBRX
Revenue
$20.1M
$38.3M
Net Profit
$-8.5M
$-61.9M
Gross Margin
90.8%
99.0%
Operating Margin
-42.0%
-169.0%
Net Margin
-42.2%
-161.8%
Revenue YoY
30.0%
407.0%
Net Profit YoY
-3.7%
-4.7%
EPS (diluted)
$-0.19
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AIP
AIP
IBRX
IBRX
Q4 25
$20.1M
$38.3M
Q3 25
$17.4M
$32.1M
Q2 25
$16.5M
$26.4M
Q1 25
$16.5M
$16.5M
Q4 24
$15.5M
$7.6M
Q3 24
$14.7M
$6.1M
Q2 24
$14.6M
Q1 24
$12.9M
Net Profit
AIP
AIP
IBRX
IBRX
Q4 25
$-8.5M
$-61.9M
Q3 25
$-9.0M
$-67.3M
Q2 25
$-9.1M
$-92.6M
Q1 25
$-8.1M
$-129.6M
Q4 24
$-8.2M
$-59.2M
Q3 24
$-7.7M
$-85.7M
Q2 24
$-8.3M
Q1 24
$-9.4M
Gross Margin
AIP
AIP
IBRX
IBRX
Q4 25
90.8%
99.0%
Q3 25
89.9%
99.4%
Q2 25
89.4%
99.5%
Q1 25
90.8%
99.6%
Q4 24
89.8%
Q3 24
90.1%
Q2 24
90.0%
Q1 24
88.7%
Operating Margin
AIP
AIP
IBRX
IBRX
Q4 25
-42.0%
-169.0%
Q3 25
-50.1%
-173.5%
Q2 25
-50.0%
-269.8%
Q1 25
-46.6%
-390.1%
Q4 24
-45.9%
-919.0%
Q3 24
-53.8%
-1314.3%
Q2 24
-51.1%
Q1 24
-70.5%
Net Margin
AIP
AIP
IBRX
IBRX
Q4 25
-42.2%
-161.8%
Q3 25
-51.6%
-209.8%
Q2 25
-55.3%
-350.3%
Q1 25
-49.1%
-784.9%
Q4 24
-53.0%
-783.4%
Q3 24
-52.2%
-1404.0%
Q2 24
-57.2%
Q1 24
-72.6%
EPS (diluted)
AIP
AIP
IBRX
IBRX
Q4 25
$-0.19
$-0.06
Q3 25
$-0.21
$-0.07
Q2 25
$-0.22
$-0.10
Q1 25
$-0.20
$-0.15
Q4 24
$-0.19
$-0.08
Q3 24
$-0.20
$-0.14
Q2 24
$-0.22
Q1 24
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AIP
AIP
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$33.9M
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-14.6M
$-500.5M
Total Assets
$115.0M
$501.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AIP
AIP
IBRX
IBRX
Q4 25
$33.9M
$242.8M
Q3 25
$39.0M
$257.8M
Q2 25
$38.0M
$153.7M
Q1 25
$42.3M
$61.6M
Q4 24
$43.8M
$149.8M
Q3 24
$48.7M
$130.4M
Q2 24
$45.8M
Q1 24
$44.8M
Stockholders' Equity
AIP
AIP
IBRX
IBRX
Q4 25
$-14.6M
$-500.5M
Q3 25
$-11.4M
$-524.3M
Q2 25
$-7.5M
$-570.7M
Q1 25
$-4.8M
$-591.4M
Q4 24
$-1.2M
$-489.1M
Q3 24
$2.2M
$-745.1M
Q2 24
$5.3M
Q1 24
$9.5M
Total Assets
AIP
AIP
IBRX
IBRX
Q4 25
$115.0M
$501.9M
Q3 25
$107.7M
$519.0M
Q2 25
$106.9M
$402.1M
Q1 25
$98.3M
$303.8M
Q4 24
$106.1M
$382.9M
Q3 24
$97.7M
$364.6M
Q2 24
$96.4M
Q1 24
$101.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AIP
AIP
IBRX
IBRX
Operating Cash FlowLast quarter
$3.2M
$-70.4M
Free Cash FlowOCF − Capex
$3.0M
$-71.3M
FCF MarginFCF / Revenue
15.1%
-186.2%
Capex IntensityCapex / Revenue
0.7%
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.3M
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AIP
AIP
IBRX
IBRX
Q4 25
$3.2M
$-70.4M
Q3 25
$3.2M
$-68.9M
Q2 25
$-2.5M
$-79.7M
Q1 25
$2.9M
$-85.9M
Q4 24
$-2.6M
$-85.1M
Q3 24
$1.1M
$-98.8M
Q2 24
$311.0K
Q1 24
$477.0K
Free Cash Flow
AIP
AIP
IBRX
IBRX
Q4 25
$3.0M
$-71.3M
Q3 25
$2.5M
$-69.6M
Q2 25
$-2.8M
$-80.8M
Q1 25
$2.7M
$-87.0M
Q4 24
$-2.7M
$-87.3M
Q3 24
$1.1M
$-101.6M
Q2 24
$264.0K
Q1 24
$281.0K
FCF Margin
AIP
AIP
IBRX
IBRX
Q4 25
15.1%
-186.2%
Q3 25
14.2%
-217.2%
Q2 25
-17.2%
-305.9%
Q1 25
16.2%
-526.9%
Q4 24
-17.3%
-1155.4%
Q3 24
7.4%
-1663.2%
Q2 24
1.8%
Q1 24
2.2%
Capex Intensity
AIP
AIP
IBRX
IBRX
Q4 25
0.7%
2.4%
Q3 25
4.1%
2.3%
Q2 25
2.2%
4.1%
Q1 25
1.1%
6.8%
Q4 24
0.3%
28.0%
Q3 24
0.2%
45.7%
Q2 24
0.3%
Q1 24
1.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AIP
AIP

License And Maintenance$17.5M87%
Variable Royalties And Other$2.6M13%

IBRX
IBRX

Segment breakdown not available.

Related Comparisons